Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis
Phase 2
- Conditions
- Early Ankylosing Spondylitis
- Registration Number
- NCT00889694
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
This study is a 12-week, randomized, placebo and positive drug controlled clinical trial to investigate whether tripterygium capsule is effective and safe in treating patients with ankylosing spondylitis. The investigators expect that the tripterygium capsule is more effective than placebo and has few adverse effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Fulfill the ESSG criteria for SpA and not fulfill any criteria for the subtype including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and inflammatory bowel disease associated arthritis.
- Disease is in active status defined by BASDAI>=40mm.
- DMARDs administration must be suspended for at least 4 weeks before screening. NSAIDs dose must be stable for at least 4 weeks before screening.
Read More
Exclusion Criteria
- Intra-articular injection of glucocorticoid within 3 months.
- Previous history of heart failure, multiple sclerosis, chronic obstructive pulmonary disease, recurrent infection, lymphoma or other tumors.
- Accompanied by fibromyalgia syndrome or other rheumatic diseases.
- Female of pregnancy or breast-feeding.
- Poor compliance or with mental diseases.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method ASAS20 12th week
- Secondary Outcome Measures
Name Time Method BASDAI20/50/70 12th week